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SUMMARY In order further to characterise and evaluate the reproducibility of human red cells coated with complement in vitro, the number of molecules of C3 subcomponents/red cell were determined by Scatchard analysis of equilibrium concentrations of bound and free antibody using 1251-labelled goat anti-rabbit IgG. A 1:1 combining ratio was assumed. Red cells coated via the classical pathway had twice as much bound C3b and C3d as alternative pathway-coated cells. Assays using different anti-C3d sera gave different amounts of bound antigen, but results with any one antiserum versus one cell type were reproducible. Anti-C3d sera raised to C3d-tryp and to C3d-KAF detected significantly different amounts of bound C3d on the same cells. Both Previous studies have suggested that LIS-tryp, The anti-C3d sera were prepared to different C3d immunogens in order to determine differences in specificity of anti-C3d-tryp versus anti-C3d-KAF. The results in the RlOl and R103 (made to the C3d-KAF antigen) appeared to detect fewer molecules/RBC on LIS-tryp cells than did R102 and R104 (raised to the C3d-tryp antigen), the difference is not statistically significant. With E-C3b(A-P)-tryp cells, however, the antisera raised to the C3d-KAF antigen (RIOl and R103) did detect significantly fewer molecules/RBC than did R102 or R104 (raised to the C3d-tryp antigen), P < 0-01. With E-C3b(A-P)-KAF cells, the antisera raised to the C3d-KAF antigen detected significantly more molecules/RBC than did antisera raised to C3d-tryp, P < 0001. With LIS-KAF cells, there was no statistical difference between the number of molecules detected by R102 or R103, but RiOl ('pure' anti-C3d-KAF) detected significantly more molecules/RBC than did RI04 ('pure' anti-C3d-tryp), P < 0-001. With LIS cells and with E-C3b(A-P) cells, significantly more molecules/RBC were detected by RlO1 than by R104, in both cases P < 0O001.
While both R84 and R87 were made to the C3d-tryp antigen, different immunogens were used in each case. R84 consistently detected a higher number of molecules/RBC on LIS-tryp and E-C3b(A-P)-tryp cells than was observed with R87; the converse was true for LIS-KAF and E-C3b(A-P)-KAF cells. 
Discussion
The present report is concerned with the quantitative assessment of control human red cells coated in vitro with C3 subcomponents, C3d in particular.
Immunochemical methods for the measurement of fluid phase C3 cannot be used for bound C3, and generally available techniques for detecting bound C3, for example, the antiglobulin test, are not quantitative. Although quantitation of the amount of fixed complement has been difficult, a few techniques have been developed. Logue et al.'3 used the C1 fixation and transfer test to study C3 in patients with autoimmune haemolytic anaemia. Although useful in a model system, the test is indirect and time-consuming. Borsos and Leonard14 developed an anti-C3 inhibition assay which was used by Fischer et al.'5 to determine the number of molecules of C3 on human red cells. They were able to show a correlation between the antiglobulin titration score and the amount of bound C3 per red cell. The authors noted that, for cells coated in vivo, the presence or absence of haemolysis was not explained by variations in the amount of IgG on the cells but could be roughly correlated with the amount of complement on the cells. Thus, the amount of C3 bound to a red cell appears to be an important determinant of haemolysis in vivo. The in vitro coated cells studied by Fischer et al. were sensitised via antibody. Low-ionicstrength media are more often used to prepare complement-coated control cells for routine use in the laboratory; the present study examines such cells.
A quantitative assay for bound complement should allow comparison of the amount of bound C3 with results obtained by conventional serological techniques. The previous work on quantitation of bound complement components has all been done with 'whole C3' and insufficiently characterised 'anti-C3' sera. It is now well recognised that it is the presence 
of the C3d subcomponent of C3 on the red cell membrane that indicates that an immune reaction has occurred in vivo. The applicability of the results with 'C3' to the biologically important C3d subcomponent needs to be investigated.
In order to quantitate the number of C3b and C3d molecules on erythrocytes, a method utilising radiolabelled antibody was used. The method is a modification of that described by Rochna and Hughes-Jones'0 for the quantitation of D antigen sites on red cells and subsequently used for quantitation of other red cell antigens. The method is based on the law of mass action using an antibody excess; the results are derived from Scatchard analysis. This method appears to be a more direct method of quantitation than the CI fixation and transfer method or the C3 inhibition assay. By using Scatchard analysis of results, different Ko values of the antisera are taken into account and do not affect the estimates of the antigen concentration. Once the antisera are prepared, the method is relatively simple. Since the method using 1251-labelled anti-rabbit IgG to determine bound anti-C3d will measure all rabbit IgG on the test cells, only antisera specific for C3 subcomponents were used. The high values observed with strongly C3b-coated red cells with R101 and R103 probably reflect the presence of both anti-C3c and anti-C3d in these reagents. When strongly complement-coated cells were assayed, the uptake of labelled anti-rabbit IgG by the cells was more than 50-fold above the non-specific uptake by control cells, and reproducibility of measurements was good. When weakly coated cells were used, the ratio of specific to non-specific uptake of labelled antiglobulin was, at times, less than twofold, and a somewhat greater variation between repeated measurements was observed.
The accuracy of the method is dependent on the accurate determination of the specific activity of the IgG fraction containing anti-C3d, and the assumption is made that the anti-C3d molecules had the same average specific activity as all the IgG molecules. Since the combining ratio of anticomplement and bound C3 subcomponents is not yet known, in these experiments the binding ratio has been taken as 1:1.
It has recently been shown'6 that soluble C3d prepared by treatment of C3-C3b with KAF differs in a number of ways from C3d prepared by treatment of C3-C3b with trypsin. The present study indicates subtle differences in the anti-C3d reactivity of antisera raised to C3d-KAF and C3d-tryp. As would be expected, the results indicate that an antiserum reacts best with the antigen against which it was raised. It appears that apparently small differences in immunogen structure can influence the specificity of the antibody.
The Scatchard curves obtained from the assays were curvilinear, indicating heterogeneity of the binding constants of anti-C3d within a sample. There were no significant differences within the six anti-C3d sera in the Ko against any or all types of cells. Thus, differences in numbers of molecules/RBC obtained using different antisera could not be attributed to variation in the equilibrium constants.
It is evident from Fig. 2 Trypsinisation of E-C3b(A-P) cells was more effective, leaving a mean of only 2300 ± 2500 C3b molecules/RBC. Both LIS-tryp and E-C3b(A-P)-tryp cells have previously been considered to have only the C3d subcomponent of C3 on their surfaces, as determined by agglutination tests with monospecific anti-C3c sera used at a concentration of 100 jug/ml.
Increasing the concentration of the anti-C3c sera to 500 ,g/ml resulted in positive agglutination tests with both LIS-tryp and E-C3b(A-P)-tryp cells (I + and I + agglutination, respectively). Increasing the time of trypsinisation up to threefold did not further reduce the number of C3b molecules on the cells. The findings suggest a population of C3b molecules bound to red cells resistant to the action of trypsin.
The resistance of E-C3b(A-P) cells to serum KAF treatment has been discussed elsewhere7 and is probably due to the presence of Bb and activated properdin on the cell surface.
Chaplin17 showed that the distinction between 'strongly' and 'weakly' coated RBC could be assessed to only a limited extent by the strength or weakness of the antiglobulin test reaction. The results presented in Fig. 4 confirm Chaplin's observation and emphasise that this is particularly true for strongly coated cells.
The results indicate that the described in vitro complement-coated red cells can be prepared and quantitated with reasonable reproducibility. Although anti-C3d sera may appear similar by immunoprecipitation techniques, differences in specificity do exist, depending on the method used to prepare the C3d immunogen. In general, anti-C3d sera raised to the C3d-KAF antigen are better for detecting C3d-KAF cells (and probably red cells coated with C3d in vivo), whereas antisera raised to the C3d-tryp antigen are better for detecting cells coated with the C3d-tryp antigen (eg, in vitro coated control cells). The results suggest that E-C3b(A-P)-tryp cells may be closest to red cells coated with C3d in vivo and may be the control cell of choice for assessing antiC3d sera.
Only two donors were used, and preliminary experiments do indicate significant differences when other donors are used or when infection or subclinical disease is present in the donors. Blood used for the preparation of control cells should, therefore, be from a regular, healthy donor to allow comparison with previous evaluations.
It is hoped that such methods will allow for the development of standard cell suspensions sensitised with known amounts of complement subcomponents, C3d in particular, and of reference antisera, of known concentration, standardised against the cells. 
